All In Biotech

Drug Trial Radar · NCT07521748

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Dec 2026

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants.RC017 is a small-molecule drug, being developed as a novel therapeutic treatment for patients with Dry Eye Disease (DED) . This study aims to evaluate the safety, tolerability and pharmacokinetics of RC017 after Single and Multiple Doses.

Conditions

  • Dry Eye

Interventions

  • RC017 Ophthalmic OintmentDrug

    Participants were randomly assigned to the 3 dose groups

  • RC017 Ophthalmic Ointment placeboDrug

    Match to RC017 Ophthalmic Ointment dose groups

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Treatment-emergent adverse events (TEAEs)Time frame: Day1 to Day 21
  2. The severity of Treatment-emergent adverse events (TEAEs)Time frame: Day 1-Day 21
  3. The incidence of Serious adverse events (SAEs)Time frame: Day 1-Day 21
  4. The severity of Serious adverse events (SAEs)Time frame: Day 1-Day 21
  5. Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parametersTime frame: Day 1-Day 21
  6. Number of participants with abnormal clinically significant clinical laboratory resultsTime frame: Day 1- Day 21
  7. Number of patients with abnormal clinically significant results from physical examinationTime frame: Day 1-Day 21

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.